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ABSTRACT
Background Sipuleucel-T (sip-T) is a Food and Drug
Administration (FDA)-approved autologous cellular
immunotherapy for metastatic castration-resistant
prostate cancer (mCRPC). We hypothesized that combining
sip-T with interleukin (IL)-7, a homeostatic cytokine that
enhances both B and T cell development and proliferation,
would augment and prolong antigen-specific immune
responses against both PA2024 (the immunogen for sip-T)
and prostatic acid phosphatase (PAP).
Methods Fifty-four patients with mCRPC treated with
sip-T were subsequently enrolled and randomized 1:1
into observation (n=26) or IL-7 (n=28) arms of a phase II
clinical trial (NCT01881867). Recombinant human (rh) IL-7
(CYT107) was given weekly×4. Immune responses were
evaluated using flow cytometry, mass cytometry (CyTOF),
interferon (IFN)-γ ELISpot, 3H-thymidine incorporation, and
ELISA.
Results Treatment with rhIL-7 was well tolerated. For
the rhIL-7-treated, but not observation group, statistically
significant lymphocyte subset expansion was found, with
2.3–2.6-fold increases in CD4 +T, CD8 +T, and CD56bright
NK cells at week 6 compared with baseline. No significant
differences in PA2024 or PAP-specific T cell responses
measured by IFN-γ ELISpot assay were found between
rhIL-7 and observation groups. However, antigen-specific
T cell proliferative responses and humoral IgG and IgG/IgM
responses significantly increased over time in the rhIL-7-
treated group only. CyTOF analyses revealed pleiotropic
effects of rhIL-7 on lymphocyte subsets, including
increases in CD137 and intracellular IL-2 and IFN-γ
expression. While not powered to detect clinical outcomes,
we found that 31% of patients in the rhIL-7 group had
prostate specific antigen (PSA) doubling times of >6
months, compared with 14% in the observation group.
Conclusions Treatment with rhIL-7 led to a significant
expansion of CD4 + and CD8+ T cells, and CD56bright
natural killer (NK) cells compared with observation after
treatment with sip-T. The rhIL-7 treatment also led to

improved antigen-specific humoral and T cell proliferative
responses over time as well as to increased expression of
activation markers and beneficial cytokines. This is the first
study to evaluate the use of rhIL-7 after sip-T in patients
with mCRPC and demonstrates encouraging results for
combination approaches to augment beneficial immune
responses.

INTRODUCTION
Immunotherapy represents a promising
therapeutic approach for a wide range of
tumor types, with numerous Food and Drug
Administration (FDA) approvals in recent
years. To date, the only FDA-
approved
immunotherapy for metastatic castration-
resistant prostate cancer (mCRPC) is sipuleucel-
T (sip-
T), a therapeutic autologous
cellular vaccine directed against prostatic
acid phosphatase (PAP). Sip-
T is generated by culturing patients’ peripheral blood
mononuclear cells (PBMC) ex vivo with
a human recombinant PAP/granulocyte-
macrophage colony-stimulating factor (GM-
CSF) fusion protein (PA2024), resulting
in activated antigen presenting cells. The
activated cellular product is then adoptively
transferred back into patients across three
doses.1 The pivotal randomized, Phase III
IMPACT trial (NCT00065442) demonstrated
a significant improvement in overall survival
(OS) compared with placebo in patients with
mCRPC, leading to FDA approval in 2010.
In IMPACT, patients with mCRPC treated
with sip-T had a median OS of 25.8 months
compared with 21.7 months in the placebo
control.2 While sip-T has proven single agent
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activity in mCRPC, the majority of treated patients do
not have clinically-
demonstrable responses (ie, prostate specific antigen (PSA) or radiographic responses).
Thus, strategies to improve its efficacy are needed. A
subanalysis of the IMPACT trial correlated development
of an immune response against PAP and/or PA2024 with
improvement in OS.3 More recently, treatment with sip-T
was shown to induce ‘antigen spread,’ or the enhancement of immune responses to a variety of tumor antigens
beyond PAP and PA2024. Together, these data suggest
that augmentation of the immune response may result in
clinical benefit.4
Interleukin-7 (IL-7) is an endogenous homeostatic cytokine that can stimulate the proliferation and activation of
T cells, prevent or reverse T cell anergy,5 and augment T
cell migration from blood into lymph nodes and peripheral organs.6 Furthermore, IL-7 can also play a role in B
cell functions, such as survival and activation.7 The IL-7
receptor (IL-7R), found on both naïve and effector T
cells, is a heterodimer comprised of CD132 (the common
γ-chain receptor) and CD127 (IL-7Rα). IL-7 is constitutively expressed and has high expression in lymphoid
tissues,8 where it binds preferentially to conventional
CD8 + and CD4+ T cells compared with regulatory CD4 +
T cells (Tregs), which typically express no or low levels of
CD127.9 10 Expression of the IL-7R has been associated
with the persistence of long-term, tumor specific CD8 +
T effector cells that are able to establish immunologic
memory in humans.11 Overall, recombinant human IL-7
(rhIL-7) has been safe and well-tolerated in human clinical trials, with injection site reactions and mild transient
constitutional symptoms being most common.12 13 Given
rhIL-7’s ability to expand and enhance lymphocyte populations and their functions, we hypothesized that the addition of rhIL-7 to sip-T would result in enhanced immune
responses and potentially improve clinical outcomes.
Here, we report a multicenter prospective randomized trial of sip-T, with or without the addition of a
rhIL-7 (CYT107). We show a significant treatment
effect of rhIL-7 on expansion of lymphocyte subsets
and enhancement of immune responses, including
on T cell proliferation and cytokine production, and
on humoral responses. While the current clinical trial
was not powered to evaluate clinical efficacy, our analysis revealed an improvement in PSA doubling times
(PSADT) with CYT107 compared with the observation
arm. Together, these data support further evaluation in
a larger clinical trial.
METHODS
Clinical study design and participants
CITN12-03 was a phase II, open-
label, multicenter,
randomized study of the administration of CYT107
(CHO cell-produced, rhIL-7, RevImmune, France) after
the completion of sip-T. Patients with asymptomatic or
minimally symptomatic mCRPC were eligible to enroll
after completion of standard of care sip-T. Between 2015
2

and 2017, 54 patients underwent informed consent and
were randomized 1:1 into observation (n=26) or rhIL-7
(n=28) arms. Prior chemotherapy for mCRPC or investigational immunotherapy was prohibited. Patients were
stratified for prior abiraterone or neoadjuvant chemotherapy with or without abiraterone in order to balance
arms. Patients were required to have prior orchiectomy or have ongoing luteinizing hormone-releasing
hormone (LHRH) receptor agonist or antagonist treatment, with documented testosterone of ≤50 ng/dL,
Eastern Cooperative Oncology Group (ECOG) of 0–1
or Karnofsky Performance Scale (KPS) ≥80%, adequate
organ function (absolute neutrophil count ≥1500/μL,
bilirubin <1.5× upper limit of normal (ULN), hemoglobin ≥10 g/dL, platelets ≥100,000/μL, aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) ≤2.5×ULN, creatinine clearance ≥60 mL/min
by the Cockcroft-Gault), and life expectancy of at least
6 months. Evaluable disease with a positive bone scan
and/or measurable disease on CT scan and/or MRI
of the abdomen and pelvis was required. Concurrent
treatment with systemic steroids, history of immunodeficiency disorder or clinically significant autoimmune
disease, or immunosuppressive therapy within 30 days
prior to enrollment were prohibited.
Procedures and assessments
After randomization, patients in the observation
and IL-7 cohorts followed the same study procedures
(online supplemental figure 1), except that week 2 and
week 4 study visits were optional for patients assigned to
observation. IL-7 (CYT107) was administered at 10 µg/
kg subcutaneously starting within 3–7 days of completion of sip-T, and continued weekly for four doses total.
The first six patients randomized to receive CYT107
were followed for an additional 4 weeks prior to the
study expanding past six patients, to ensure safety and
tolerability of the selected CYT107 dose. Patients in the
IL-7 cohort were treated for one cycle (four doses total)
or until unacceptable adverse event(s), intercurrent
illness preventing further administration of treatment,
or disease progression.
Imaging was performed at baseline and then every 12
weeks post therapy and at time of removal from study
for progressive disease. Radiographic progression-free
survival was based on RECIST V.1.1 and Prostate Cancer
Working Group 2 criteria. For patients with RECIST
V.1.1 measurable disease, best overall response was the
best response recorded from the start of the treatment
until disease progression/recurrence (the smallest
measurements recorded after treatment initiation were
used as the reference for progressive disease). Patients
were followed for 53 weeks or until death, whichever
occurred first.
Complete blood counts (CBCs) with differentials and
PSA levels were locally measured at CLIA-certified laboratories using longitudinally collected blood samples.
Absolute lymphocyte and neutrophil counts were
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collected from CBCs, and neutrophil to lymphocyte
ratios (NLRs) were calculated from these numbers and
then normalized to the baseline NLR value. Although
sip-T rarely leads to PSA declines (2.6% in the IMPACT
trial,2 analysis of PSADT was performed to investigate
the potential impact of rhIL-7 on PSA responses. PSADTs
were calculated using the MSKCC PSADT Nomogram
(https://www.m skcc.o rg/n omograms/p rostate/p sa_
doubling_time),14 with available PSA data points starting
at baseline. PSA measurements were used regardless of
radiographic responses; however, those collected after
patients started a subsequent anticancer therapy were
excluded from the PSADT calculations. The ‘percent
change in PSA from baseline’ was calculated using week
1 as baseline and comparing subsequent PSA values
at pre-specified time points (weeks 6, 11, 23, and 53)
until patients were off-study or started new anti-cancer
treatment.
Trial end points
The primary end point of the trial was a comparison
of the magnitude of interferon (IFN)-γ T cell ELISpot
responses to PA2024 measured at week 11 in both
cohorts. Secondary end points included the clinical
efficacy and tolerability of sip-T plus CYT107 compared
with sip-T alone, characterization of T cell and antibody responses to PAP and PA2024, and the effects of
CYT107 on the immune competence of patients with
advanced prostate cancer. The protocol was powered
to detect differences in ELISpot responses between
the groups (as the primary endpoint) and was not
powered to discern effects on OS or other clinical
parameters.
Statistical analyses
For all correlative assays, results were compared
tailed unpaired
between treatment groups using two-
student t-tests for unequal variances, with the threshold
for meeting the null hypothesis set at 0.05. For results
compared over time in the same individuals, data were
analyzed using paired two-tailed t-tests for unequal variances, with the alpha set at 0.05.
PBMC isolation
PBMC were isolated using Ficoll-Hypaque.15 Cryopreserved PBMCs were thawed (RPMI 1640+10% human
serum,+2 mM L-glutamine,+100 units penicillin–streptomycin)+50 U/mL Benzonase, washed and resuspended at 2×106 cells/mL, and rested overnight at
37°C, 5% CO2 before use in mass cytometry (CyTOF),
proliferation and ELISpot assays.
Flow cytometry
Whole blood (100 µL) was transferred to BD Trucount
Tubes within 30 hours of collection and labeled with a
12-color antibody panel to identify PBMC subpopulations
as described.15

CyTOF
Eight subjects from each arm were analyzed using high
dimensional single cell analysis by CyTOF. On thawing,
each sample was split into unstimulated and stimulated
wells and rested overnight. Stimulated cells were treated
with PMA/ionomycin for 4 hours. Brefeldin A and
monensin (both at 5 µg/mL per sample, Sigma-Aldrich,
St Louis, Missouri) were added to both stimulated and
unstimulated cells, as was anti-CD107a conjugated with
151Eu. Then, cells were stained for surface markers and
intracellular cytokines as described previously16 with the
antibody panel described in online supplemental table
1. Data collected were normalized using the Nolan Lab
MATLAB normalizer (https://github.com/nolanlab/
bead-normalization/releases) and then analyzed with
Cytobank (www.cytobank.org).
T cell proliferation assay
Proliferation assays were performed in blinded fashion
at Dendreon as described.3 Proliferation and ELISpot
assays were run in parallel using the same aliquot of
thawed PBMC. PBMC were plated at 100,000 cells/well
and tested in triplicate with: media alone, 50 µg/mL
PA2024, 25 µg/mL PAP, 1 ug/mL CEFT (Cytomegalovirus, Epstein-Barr virus, Influenza virus, and Tetanus
toxin peptides; positive control), and 3 µg/mL PHA-L
(phytohemagglutinin-L; positive control). Plates were
pulsed with 3H-thymidine, and 3H-thymidine incorporation measured using a MicroBeta 2450 Scintillation
Counter. Results were obtained as counts per minute
and are presented as stimulation indices (SI), defined
as the ratio of the test well mean divided by the media
alone well mean.17
T cell ELISpot
Antigen-specific IFN-γ release was determined using a
direct 48 hours ELISpot assay qualified3 and performed
at the CITN Central Lab. MISPS4W10 plates (Millipore)
were coated with 15 µg/mL mouse anti-human IFN-γ
(MabTech clone 1-D1K) overnight at 4°C, then blocked.
PBMC were plated at 300,000 cells/well (50,000 cells/
well for PHA-L). Antigen conditions tested in triplicate
included media alone, 50 µg/mL PA2024, 25 µg/mL
PAP, 1 ug/mL CEFT, and PHA-L at 10 µg/mL. After a 48
hours incubation at 37°C, 5% CO2, plates were washed
and biotinylated mouse anti-human IFN-γ monoclonal
antibody (clone 7-B6-1, MabTech) was added to wells.
Plates were washed with PBS, developed with StrepAvidin-ALP (1:1000) and NBT/BCIP. Plates were dried at
room temperature (RT) until image capture and spot
counting by a CTL ELISpot reader with Immunospot
software. Data are presented as ‘cSPW’ (background-
subtracted ‘Corrected Spots/Well’).
ELISA
ELISAs were performed in blinded fashion at Dendreon
using the Agilent BioCel robotic system. Assay plates
were coated with 0.5 µg/mL of PAP, PA2024, or tetanus

Pachynski RK, et al. J Immunother Cancer 2021;9:e002903. doi:10.1136/jitc-2021-002903

3

J Immunother Cancer: first published as 10.1136/jitc-2021-002903 on 27 August 2021. Downloaded from http://jitc.bmj.com/ on August 31, 2022 at Washington University School of Medicine
Library &. Protected by copyright.

Open access

antigens and blocked with Superblock (Thermo Scientific, Rockford, Illinois). Twofold serially diluted serum
was incubated on plates for 1.5 hours, washed, then
incubated with goat-
anti-
human HRP conjugate at
1:4000 for anti-human IgG +IgM or at 1:20,000 for anti-
human IgG. After 1 hour at RT, plates were washed and
TMB was added and absorbance read at 450 nm. Titers
>400 are typically considered positive in this assay, after
taking background into account.3
Anti-drug antibody testing
Anti-drug antibody (ADA) testing was performed at Eurofins I ADME Bioanalyses (France) on pre-dose (week 1)
and post-dose (week 11) sera from all subjects receiving
CYT107.

RESULTS
Demographics
A total of 54 patients were enrolled, with 26 in cohort 1
(observation) and 28 in cohort 2 (rhIL-7). Overall, the
two cohorts were generally well-balanced in terms of age
and ethnicity (table 1). While there was an imbalance
of African-
American/black patients between groups,
the absolute numbers were small and the vast majority
of patients in each cohort were white (rhIL-7: 89.3%,
observation: 80.8%). ECOG performance status of 1
was assessed in 7 (26.9%) and 4 (14.3%) patients in the
observation and rhIL-7 cohorts, respectively, with the
remainder of patients being ECOG 0. All patients had
confirmed mCRPC, with bone metastases present in
17 (73.9%) patients in the observation and 17 (65.4%)
patients in the rhIL-7 groups. Of note, sip-T is not recommended for patients with visceral disease, per National
Comprehensive Cancer Network (NCCN) guidelines.
Differences in absolute lymphocyte counts and neutrophil-tolymphocyte ratios with rhIL-7 treatment
Absolute lymphocyte counts, calculated from CBC, were
significantly increased in rhIL-7-treated subjects at weeks 3,
4, 6 and 11 compared with observation subjects (all≤0.03,
figure 1A). Absolute neutrophil counts were not different
between the groups at any time point (figure 1B). NLRs,
normalized to the baseline NLR value, were calculated;
a statistically significant decrease in the normalized NLR
was found at week 6 in the rhIL-7 compared with the
control group (p=0.007) (figure 1C).
rhIL-7 treatment results in significant expansion of
lymphocytes
We further investigated the role of rhIL-7 in stimulating
T treatment by whole
lymphocyte expansion after sip-
blood flow cytometry. CD45 + lymphocytes were significantly expanded in the rhIL-7 (n=22) compared with the
observation group (n=14) at week 6 (p=0.007, figure 1D).
Similarly, significant increases in the absolute numbers
of CD4 + T (p=0.007, figure 1E) and CD8 + T (p=0.001,
figure 1F) and total CD3 + T, and CD56bright NK cells
4

Table 1

Patient characteristics at baseline
IL-7
(N=28)

Obs
(N=26)

Total
(N=54)

 N

28

26

54

 Median

68

66.5

67

 Min–max

51–81

46–81

46–81

 White

25 (89.3%)

21 (80.8%)

46 (85.2%)

 Black or African-
American

2 (7.1%)

4 (15.4%)

6 (11.1%)

 Not reported

1 (3.6%)

1 (3.8%)

2 (3.7%)

 Median

12.9

12.2

12.7

 Min–max

10.9–14.4

10.3–14.7

 

Variable
Age

Race

Baseline hemoglobin

Baseline alkaline phosphatase
 Median (U/L)

70.5

70.0

70.0

 Min–max

39–151

29–1113

 

 Mean

29.0

35.6

31.9

 Median

5.8

15.4

10.6

 Min–Max

0.11–156.4

0.47–202.7

 

 0

24 (85.7%)

19 (73.1%)

43 (79.6%)

 1

4 (14.3%)

7 (26.9%)

11 (20.4%)

12 (46.2%)

14 (60.9%)

26 (53.1%)

Baseline PSA*

ECOG

Disease distribution†
 Bone only
 Lymph node only

6 (23.1%)

4 (17.4%)

10 (20.4%)

 Mixed

5 (19.2%)

3 (13.0%)

8 (16.3%)

*For baseline PSA data, IL-7 had n=26, Obs had n=21.
†For disease distribution by imaging, IL-7 had n=26, Obs had
n=23.
ECOG, Eastern Cooperative Oncology Group; IL-7, interleukin-7;
Obs, observation; PSA, Prostate specific antigen.

(both data not shown) were observed in the rhIL-7 group
at week 6 compared with the observation group. Moreover, the rhIL-7-treated group exhibited statistically significant increases in CD4 + and CD8+ T cells at week 6 (both
p<0.001), and week 11 (both p<=0.004) compared with
baseline (figure 1E,F). However, the observation group
did not exhibit such changes over time. Of the PBMC
subpopulations identified by our flow cytometry panel,
fold-increases were greatest at week 6 among CD8 + T
cells (2.6-fold), CD4 + T cells (2.3-fold), CD56br NK cells
(2.3-fold), and B cells (1.8-fold)(figure 1G). By contrast,
the observation group did not exhibit such increases
(figure 1H).
High-dimensional CyTOF analysis
To further understand the impact of rhIL-7 on major
PBMC subpopulations after sip-T, we performed CyTOF
analysis on eight patients from both arms. This subset
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Figure 1 Lymphocyte expansion among interleukin (IL)-7-treated and observation cohorts. Absolute cell counts (cells/µl
blood) were calculated from local complete blood count data to determine (A) absolute lymphocyte counts (ALC), (B) absolute
neutrophil counts (ANC), and (C) neutrophil:lymphocyte ratios (NLR) relative to the baseline NLR. Mean and SD are shown for
the IL-7-treated (red) and observation (black) cohorts. Blue arrows indicate the weekly dosing schedule for recombinant human
(rh)IL-7. Asterisks indicate statistically significant differences in cell counts between the cohorts (for ALC, p=0.005 at week 3,
p=0.02 at week 4, p=0.009 at week 6 and p=0.03 at week 11; for NLR relative to baseline, p=0.007 at week 6; all t-tests for
unequal variances). Lymphocyte subset expansion was monitored using flow cytometry as described at weeks 1, 6 and 11
(D–H). Mean and SD are shown for the rhIL-7-treated (red) and observation cohorts (black, (D–F). Asterisks indicate statistically
significant differences in cell counts between the cohorts (at week 6: for CD45 + cells, p=0.007; for CD4 + cells, p=0.007; for
CD8 + cells, p=0.001; all t-tests for unequal variances). Bars at the top of each plot indicate statistically significant differences
between time points for the IL-7-treated cohort (red). No statistically significant differences between time points was found
for the observation cohort. Log fold-changes from baseline for specific PBMC subsets is shown for the rhIL-7-treated (G) and
observation (H) cohorts.

of subjects was chosen based on strength of individual
antigen-
specific responses seen by ELISpot (online
supplemental figure 2) and availability of adequate
numbers of PBMC. The flow cytometric gating strategy
for these experiments is shown in online supplemental
figure 3).
To evaluate T cell functionality and anergy, the expression of immune checkpoint and costimulatory molecules
was analyzed. In the rhIL-7-treated group, a clear decrease
of PD-1 (programmed cell death protein 1) expression
was observed at week 6 compared with baseline on CD4+,
CD8 + and γδ T cells (figure 2B). Decrease in surface
expression of another inhibitory molecule, CTLA-4,
occurred on CD4 + T cells at week 6 in both the rhIL-7
and observation groups, and in the γδ T cells in the observation group only (figure 2A). We also detected a higher
expression of PD-L1(programmed cell death ligand 1) on
CD4 + T, CD8 + T and NK cells, which might be due to
the decrease in PD1 (figure 2C). Finally, CD137 (4-1BB)
expression also increased on CD4 + and CD8+ T cells
and slightly on NK cells at week 6 in the rhIL-7 treated

group but not the observation group. The same trend
was observed on γδ T cells in the rhIL-7 treated group
but it did not reach statistical difference (figure 2D).
Altogether, these data support the hypothesis that rhIL-7
treatment potentiates the sip-T therapy by increasing T
and NK cell functionality and costimulatory potential, as
well as diminishing T cell anergy markers.
To further investigate T cell functionality, we analyzed
pro-inflammatory intracellular cytokine expression with
or without PMA/ionomycin stimulation among T cells,
NK cells, and γδT cells (Figure 2 and online supplemental
table 1). Increases in intracellular cytokines by week 6
were found commonly among CD4 + T cells, γδT cells and
CD56 + NK cells in the rhIL-7-treated cohort (figure 2).
However, statistically significant increase in intracellular cytokine levels were seen rarely in the observation
cohort. Stimulated CD8 + and γδT cells already expressed
high amounts of tumour necrosis factor alpha (TNFα)
independently of the rhIL-7 treatment so the effect of
rhIL-7 treatment on these populations was not evaluable
(figure 2G). Interestingly, IL-6 expression in CD4 + T
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Figure 2 CyTOF analyses. CYT107 induced an increase of pro-inflammatory cytokine expression by different lymphocyte
subsets. (A–C) Immune checkpoint expression and (D) costimulatory factor CD137 expression on T and NK cells were assessed
by the CyTOF analysis at baseline (W01) and week 6 (W06) following PMA/Ionomycin stimulation for 4 hours. PD-1 expression
(B) decreased while PD-L1 and CD137 expression (C,D) increased on T cells on treatment by CYT107. (E–H) IL-2, IFN-γ, TNF-α
and IL-6 intracellular expression in NK and T cells were analyzed by CyTOF in a subset of nine patients in both arms at baseline
(W01) and week 6 post-treatment (W06) after stimulation by PMA/Ionomycin for 4 hours. (I–L) Intracellular cytokine expression
in CD4 T cells memory subsets. On stimulation by PMA/Ionomycin, IL-2 and TNF-α expressions (I,K) were upregulated among
all naïve and memory subsets following treatment with CYT107 while IFN-γ and IL-6 (J,L) were not increased in the terminally
differentiated effector cells. Histograms represent the mean+SEM. Multiple comparisons were made using mixed-effects model
or two-way ANOVA. *p<0.05, **p<0.01, ***p<0.001. CyTOF, mass cytometry; IFN, interferon; IL, interleukin; NK, natural killer;
TNF, tumor necrosis factor; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; ANOVA, analysis of
variance.

cells was increased with stimulation in the rhIL-7 group
at week 6 compared with baseline; although typically
expressed by stromal or antigen presenting cells, IL-6
expression has been shown in CD4 + T cells18 and may
play a role in the mobilization and antitumor activity of
NK cells19 (figure 2H). As CD4 + T cells were particularly
sensitive to rhIL-7 potentiation, we investigated whether
rhIL-7 treatment targeted a specific CD4 + memory T cell
subset (figure 2I–L). Surprisingly, we detected an increase
of IL-2 and TNFα expression across all the naïve and
memory subsets in the rhIL-7 arm at week 6 (figure 2I and
K), while IFN-γ and IL-6 were upregulated in the naïve,
central memory and effector memory subsets (figure 2J
and L), demonstrating that rhIL-7 appears to broadly
stimulate the entire CD4 + T cell compartment the most,
among CD4+, CD8+, γδ+ T cells and NK cells. Potentially
relevant to the IFN-γ ELISpot results, fewer CD4 + T cells
demonstrated intracellular IFN-γ-positivity than for IL-2,
IL-6 or TNF-α.
T cell IFN-γ and proliferative responses
A major hypothesis and the primary end point of this clinical trial was that treatment with rhIL-7 would enhance T
cell IFN-γ responses to PA2024 by week 11 compared with
observation. However, no significant increase in T cell
IFN-γ response to PA2024, PAP, or CEFT was detected in
the rhIL-7 group (n=28) compared with the observation
group (n=24) at week 11 (online supplemental figure 2).
6

Furthermore, no significant increases in IFN-γ responses
to any of the antigens over time was found for either
group. However, it is important to note that while the
percentage of antigen-specific responses as measured in
the ELISpot assay—which uses a fixed number of PBMC/
well—was not different between the two groups, the ~2
to 3-fold increases in total body lymphocytes (figure 1A)
and ~2-fold increases in CD4 and CD8 T cells (figure 1G)
seen in the IL-7 arm would—in effect—translate into
overall higher total absolute numbers of antigen-specific
effector T cells in the body.
Antigen-specific T cell proliferative responses against
PA2024, PAP, and CEFT were also measured (figure 3).
It is worth noting that background counts incorporated
in the absence of antigen were unusually high in both
groups at baseline, with similar results at later time points.
Since all of the samples demonstrated high levels of background, no results were excluded on the basis of this
characteristic. Despite the high bar required to overcome
this background proliferation, likely due to prior sip-T
treatment, robust antigen-specific proliferative responses
(SI), particularly to PA2024, were identified. No statistically significant differences were observed between treatment arms at any time point, but proliferative responses
to PA2024 and PAP increased significantly over time in
the rhIL-7-treated group in contrast to CEFT responses.
Only PA2024-
specific proliferative responses increased
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Figure 3 Proliferative responses to PA2024 and PAP
increase over time. Each symbol represents data from an
individual patient in either IL-7-treated (left panels, red) or
observation (right panels, black) arms obtained at baseline
(week 1, W01), and weeks 6 (W06) and 11 (W11). Mean
stimulation index for each antigen tested (PA2024, PAP, and
CEFT) at each time point is indicated by the black columns.
Bars at the top of each plot indicate statistically significant
differences between time points for the recombinant human
IL-7-treated (red) and observation cohorts (black). IL,
interleukin; PAP, prostatic acid phosphatase; SI, stimulation
indices; CEFT, CMV/EBV/infleunza/tetanus control peptides.

significantly over time in the observation group. Proliferative responses to PAP were less robust than to PA2024 at
all time points (p<0.0001 for all). However, PAP responses
increased significantly over time in the rhIL-7-
treated
group (p=0.05 at week 6, p=0.02 at week 11) but not in
the observation group (figure 3).
Antigen-specific humoral responses with rhIL-7 treatment
As IL-7 has been shown to play roles in B cell activation and
function,7 we examined the impact of rhIL-7 administration on antibody responses. IgG alone and IgG plus IgM
antibody responses to PA2024 and PAP were measured at
baseline and weeks 6 and 11. The antibody titers shown in
figure 4 represent the greatest serum dilution yielding a
positive result. As all patients had previously been treated
with sip-
T, it was not surprizing that positive PA2024-
specific IgG responses were detected at baseline in 16%
(4/25) and 30% (6/20) of rhIL-7-treated and observation group patients, respectively, before rhIL-7 treatment.
Positive baseline PAP IgG responses were also detected in
30% (8/27) and 25% (5/20) of rhIL-7-treated and observation group patients, respectively. Even higher numbers

Figure 4 Antibody responses to both PA2024 and PAP
increase over time in rhIL-7-treated patients. Each symbol
represents data from an individual patient in either rhIL-7-
treated (left panels, red) or observation (right panels, black)
arms obtained at baseline (week 1, W01), and weeks 6
(W06) and 11 (W11). Both IgG and IgG plus IgM responses
against PA2024 and PAP antigens were evaluated using
serially diluted sera and established positivity thresholds
as described.3 Mean antibody titers at each time point are
indicated by the black lines. Bars at the top of each plot
indicate statistically significant differences between time
points for the rhIL-7-treated (red) and observation cohorts
(black). IL, interleukin; PAP, prostatic acid phosphatase; rhIL7, recombinant human IL-7.

of patients had positive IgG/IgM responses to PA2024
(85% (23/27) in rhIL-7% and 90% (17/19) in observation groups) and PAP (89% (23/26) in rhIL-7% and 63%
(12/19) in observation groups) at baseline. These data
are consistent with previous studies showing induction
of humoral PA2024 and PAP-specific immune responses
with sip-T therapy.3 No statistically significant differences
were found between the rhIL-7-treated and observation
cohorts at any time point. However, despite the presence
of positive antigen-specific antibody responses at baseline, IgG and IgG/IgM titers to both PAP and PA2024
significantly increased by week 6 in the rhIL-7 group. By
contrast, only the PA2024 IgG/IgM response was significantly increased at week 6 in the observation group.
Adverse effects with rhIL-7 treatment after sip-T
The safety, tolerability, and related adverse events (AE)
were collected in both the observation and rhIL-7
groups over the course of the trial and assessed using the
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National Cancer Institute Common Terminology Criteria
for Adverse Events V.4.0. After the completion of sip-T,
patients in the observation arm generally tolerated it well,
with 6/26 (23.1%) having any grade related AEs and 0/26
(0%) having any related grade 3/4 AEs (online supplemental table 2). Overall, the rhIL-7 cohort had higher
rates of treatment-related AEs, with 26/29 (92.9%) having
any AE, and 2/28 (7.1%) having grade 3 or greater AEs.
Injection site reactions, all grades 1–2 in 21 of 28 patients,
comprised the majority of the AEs in the rhIL-7 group.
The two grade 3+ AEs were hypertension and diarrhea.
Fatigue in 7/28 (25%), skin disorders in 7/28 (25%),
pruritus/urticaria in 3/28 (10.7%) each, and arthralgias
in 3/28 (10.7%), were the next most common grade 1–2
AEs. Overall, the addition of rhIL-7 following sip-T was
well tolerated with no treatment-related grade 5 AEs, and
no unexpected toxicity compared with prior studies. Only
1 of 28 subjects tested positive for ADA in confirmatory
testing but was not tested for neutralizing antibodies.
Clinical efficacy of rhIL-7 treatment after sip-T
A secondary objective of the study was to assess clinical
outcomes. While insufficient data were available to determine statistically powered differences, we saw no significant differences in radiographic progression free survival
(rPFS) or in OS between the two groups (online supplemental figure 4). Intriguingly, the IL-7 group does show
tails of the curves in both OS and rPFS, with median OS
not yet reached in the IL-7 group. Importantly, however,
the study was not adequately powered to determine differences in these or other clinical outcomes and long-term
follow-up was completed on December 31, 2018; thus
these findings can only be hypothesis-generating.
Treatment with sip-T typically does not result in robust
PSA responses, with only 2.6% of patients in the IMPACT
trial having a >50% PSA response (PSA50).2 Regardless, we also analyzed PSA levels for potential treatment
effects. Baseline PSA measurements between groups were
not statistically different (figure 5A), nor were any significant differences in mean PSAs found between groups
at any time point. We calculated the per cent change in
PSA from baseline at pre-specified time points (weeks 6,
11, 23, and 53). For the rhIL-7-treated group, a statistically significant decrease in the PSA per cent change
from baseline was found only at week 6 compared with
the observation group (p=0.042, figure 5C). Notably,
PSADT of >6 months, calculated using the validated
MSKCC nomogram,14 were found to be more than twice
as common in the IL-7-
treated group compared with
the observation group (31% vs 14%) (figure 5B). While
not sufficiently powered to detect such PSA differences,
we found higher rates of both PSA50 (4.3% vs 0%) and
any negative per cent change in PSA (30.4% vs 10.5%)
at week 6 in the rhIL-7-treated group compared with the
observation group.
The two rhIL-7-treated subjects (numbers 51 and 34)
with exceptional PSADT responses were diagnosed with
lymph node only involvement in the abdomen or pelvis,
8

Figure 5 PSA data. (A) Baseline PSA levels are shown for
each patient in the IL-7-treated (red) and observation (black)
cohorts. (B) PSA doubling time (PSADT, in months) was
calculated using the Memorial Sloan-Kettering calculator
(https://www.mskcc.org/nomograms/prostate/psa_doubling_
time). Each bar represents data from a single patient; PSA
values obtained after patients started another anticancer
therapy were not used for calculations. Two patients in the
IL-7-treated cohort had negative PSADT values calculated
due to persistent reductions in their PSA values; these were
arbitrarily assigned PSADT of 100 months as previously
described,29 and are indicated by asterisks. The percentage
of patients with a PSADT above the threshold of 6 months
are shown. (C) Per cent change in PSA levels from baseline to
week 6 in individual patients (IL-7, n=23; observation, n=19).
IL-7, interleukin-7; OBS, observation.

had alkaline phosphatase levels within the normal range,
and stable disease as a best radiographic response. They
were among 16 of 28 (57%) of rhIL-7 treated patients
with stable disease; 13 of 26 (50%) subjects in the observation group also had stable disease. Only one subject
in the rhIL-7 group had a partial response. It is worth
noting that 5/28 (18%) and 10/26 (38%) subjects in the
rhIL-7 and observation groups, respectively, did not have
response measurements available. Of these two subjects,
subject 51 had very robust immune responses by nearly
all assays tested; PA2024 and PAP-specific proliferation
increased 3.6-fold (80th percentile) and 2.1-fold (76th
percentile), respectively, by week 6, while PA2024-specific
IgG levels also increased 2.6-fold (83rd percentile) by
week 6 among rhIL-7-treated patients. Both subjects had
relatively robust CD4 + T cell expansion at 2.4-fold and
2.5-fold increases at week 6, while subject 51 also had
a substantial B cell expansion of 2.8-fold. In addition,
both had NLR decreases of 60% by week 6 which were
at the 75th (subject 34) and 83rd (subject 51) percentiles. Notably, both demonstrated robust IFN-γ ELISpot
responses to PA2024 and PAP at both weeks 6 and 11.
Subject 34 had PA2024-specific increases of 2.3-fold (76th
percentile) and ninefold (92nd percentile) at weeks 6
and 11, respectively, while subject 51 had 1.6-fold (64th
percentile) and 4.1-
fold (79th percentile) at weeks 6
and 11, respectively. Finally, subject 34 had PAP-specific
IFN-γ ELISpot increases of 61.2-fold (100th percentile)
and 63.2-fold (86th percentile) at weeks 6 and 11, respectively, while subject 51 had increases of sevenfold (76th
percentile) and 2.8-fold (71st percentile) at weeks 6 and
11, respectively. With respect to the OS of these exceptional PSA responders, we have limited data as protocol-
specified follow-up was completed at week 53; however,
both of these patients were alive at last follow-up. Taken
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together, these data suggest rhIL-7 treatment may alter
prostate cancer disease kinetics and related immune
parameters.
DISCUSSION
Here, we present the first study to evaluate the use of
rhIL-7 in patients with mCRPC. Patients were enrolled
and randomized after receiving sip-T, a treatment known
to induce both cellular and humoral immune responses,
including antigen-
specific T cell responses. Given the
beneficial effects of rhIL-7 on lymphocyte expansion and
function, we hypothesized that rhIL-7 treatment immediately following standard of care sip-T would augment
immune responses, and potentially clinical responses,
compared with the sip-T-treated observation group. While
the primary endpoint of a statistically significant difference in PA2024-specific T cell IFN-γ ELISpot responses
was not met, significant increases in antigen-specific T
cell proliferative and humoral responses were induced
by rhIL-7 over the course of treatment. Moreover, these
significantly enhanced T and B cell responses targeted
the PAP antigen in addition to PA2024. Not surprisingly,
treatment with rhIL-7 resulted in a significant expansion of total CD45+, CD4+, and CD8 + cells at week 6
compared with observation. Finally, encouraging clinical
findings were seen in the rhIL-7-treated group compared
with the observation group, with decreased PSA values at
week 6 and an increase in the number of patients with
PSADTs of >6 months.
Our data confirm that administration of rhIL-7 can
induce significant in vivo increases in lymphocyte subsets,
including CD4 + and CD8+ T cells, leading to a statistically significant decrease in NLR at week 6. The total
absolute increase in lymphocyte populations seen with
rhIL-7 treatment also suggests that, while the ‘frequency
within PBMC’ of antigen specific T cells was not increased
(as measured by ELISpot), the total pool (ie, total body
specific effector T cells was
lymphocytes) of antigen-
increased (along with other T cells). This is because the
ELISpot assay only measured specific T cells within a
fixed number of PBMC, while flow cytometry and ALC
measure absolute numbers. In-depth mechanistic CyTOF
analyses on stimulated PBMC from a subset of patients
also revealed significant increases in beneficial ‘pro-
inflammatory’ cytokines (IL-2, IFN-γ, TNF-α and IL-6)
in the rhIL-7-treated group, particularly among CD4 + T
cells.
Multiple factors likely contributed to our inability to
reach the primary end point. First, the study was intended
to enroll 40 patients per arm in order to identify a twofold
difference in IFN-γ ELISpot responses between the
groups. Due to unexpected limitations on the availability
of rhIL-7 during the trial, only 54 total patients were
enrolled (with 52 samples evaluated) out of the planned
80, limiting our statistical power to discern differences
between the groups. Patient retention in the observation
arm over time, in the absence of a placebo, was also a

challenge. Another possible confounder is the observation that preceding sip-T therapy had initiated effects
on both T and B cell responses, leading to higher ‘background’ levels of immune stimulation detected in both
groups prior to randomization to observation or treatment with rhIL-7. These ‘baseline’ immune responses,
measured after standard-of-care therapy with sip-T, effectively ‘raised the bar’ even higher for the ability to detect
differences between the two groups, as we did not have
access to patient samples or data prior to treatment with
sip-T. Alternatively or in addition, the activated state of
immune cells at baseline documented by higher expression levels of CTLA-4 and PD-1 could have made T cells
more refractory to subsequent stimulation by rhIL-7 than
if they had not been previously stimulated by sip-T. Finally,
the CyTOF analyses demonstrated that even with mitogen
stimulation, intracellular T cell IFN-γ levels were modest
and similar between rhIL-7 and observation groups,
consistent with our inability to detect statistically significant changes in this parameter between groups using the
antigen-stimulated ELISpot assay.
Clinically, we confirmed that rhIL-7 treatment was
generally well tolerated, with expected injection site and
skin reactions, and an acceptable safety profile in line
with prior studies. We did not expect to detect meaningful efficacy changes with the addition of rhIL-7 to
sip-T, as the study was not powered to detect these. Unexpectedly, however, we observed a decrease in the PSA
change from baseline in the rhIL-7 arm at week 6, and an
increase in the number of patients having PSADTs of >6
months, compared with observation. Given that baseline
PSAs were not significantly different between groups,
this favorable change in PSADTs could suggest a clinical
impact of the significant lymphocyte expansion in the
rhIL-7 group, but this hypothesis will have to be formally
explored in larger, adequately powered trials.
Our study had several weaknesses. We only tested
immune responses in peripheral blood, limiting our
ability to identify direct relationships between rhIL-7
administration and antitumor responses in the tumor
microenvironment. As mentioned, early termination of
enrollment led to a smaller than expected trial size, and
thus reduced the power of our analyses. There were also a
greater number of African-Americans (AA) in the observation group (n=4) compared with the IL-7 (n=2) group.
As AA patients with mCRPC may have improved responses
to sip-T20, this imbalance may have contributed to the
outcomes; regardless, we were still able to show significant
differences in immune responses, week 6 PSA responses,
as well as improved PSADTs in the IL-7 group. While
patients were maintained on ADT, they were allowed to
be treated with additional FDA-approved agents or enroll
in additional clinical trials during follow-up after completion of sip-T and subsequent rhIL-7 or observation. Thus,
these subsequent therapies could have altered clinical
responses seen; importantly, PSA data collected from
patients after starting subsequent anticancer therapies
was not included in PSA or PSADT calculations. Clinical
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follow-up was stopped at week 53 per protocol, which also
limited our ability to determine any potential impact of
IL-7 on long-term OS in these patients, which has been
seen in other mCRPC immunotherapy studies.21
To date, sip-T remains the only FDA-approved immunotherapy for unselected patients with mCRPC and the
search for additional immunotherapeutics for patients
with prostate cancer continues. Single agent checkpoint inhibitor trials of ipilimumab, nivolumab, and
pembrolizumab have been disappointing in mCRPC. For
example, single agent pembrolizumab showed an ORR
of 5% in PD-L1 positive patients,22 while single agent
atezolizumab produced a PSA response in only 8.6% of
patients.23 Another large phase III trial of a single agent
immunotherapy, the PSA-based vaccine Prostvac-VF, was
also recently reported as negative when compared with
placebo in chemotherapy-naïve patients with mCRPC.24
The failure of such single agent trials supports the rationale and need for future combinatorial approaches such
as ours. Other combination approaches are currently
being studied using various immunotherapeutic agents
in mCRPC, including combination ipilimumab and
nivolumab,25 PAP-
encoding DNA vaccine in combination with pembrolizumab,26 attenuated listeria vaccine
targeting PSA in combination with pembrolizumab,27
and other innovative multi-
immunotherapy adaptive
approaches.28
While our data clearly demonstrated rhIL-7’s effects on
CD4 + and CD8+ T cell expansion when given after si-T,
the limitations of our study impaired our ability to find
associations between the immune findings and clinical
outcomes. The finding that greater numbers of CD4 +
T cells capable of producing pro-
inflammatory cytokines were detected in rhIL-7-treated individuals raises
the question of whether sequencing of rhIL-7 before or
during sip-T treatment may produce more naive T cells
for sip-T stimulation, ultimately leading to improved clinical responses. It is also interesting to consider whether
patients with lower (or higher) baseline ALC might incur
more clinical benefit from rhIL-7. Overall, our data indicate an acceptable safety profile and immunological
rationale for using rhIL-7 in combination with sip-T as
well as other immunostimulatory agents, such as checkpoint inhibitors and targeted radiotherapeutics, together.
We believe that additional combination studies such as
these are needed to improve outcomes for patients with
mCRPC.
In summary, while sip-T remains a backbone of prostate
cancer immunotherapy, clinical studies to date have made
it clear that single agent immunotherapies, such as checkpoint inhibitors, are not efficacious in mCRPC. Thus,
combination therapies must be pursued. A strength of
this clinical trial was the cooperative, multi-institutional,
randomized nature of the study. It is also the first to evaluate the addition of a rhIL-7 product in patients receiving
sip-
T. rhIL-7 treatment was safe and well tolerated.
Among rhIL-7-treated patients, we demonstrated a significant expansion in lymphocyte populations, a significant
10

reversal of the NLR, and significant increases in antigen-
specific T and B cell responses, including to PAP. Findings
from these studies support further exploration of rhIL-7
as part of a combination immunotherapy approach.
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IL7 (N=28)

Supplemental Table II. Definitely, Possibly, or Probably
Related Treatment-Emergent Adverse Events

Adverse Event

Any Grade

J Immunother Cancer

Observation (N=26)

Grade 3 or 4 Any Grade

Grade 3 or 4

Any Adverse Event

26 (92.9%)

2 (7.1%)

6 (23.1%)

0 (0%)

Injection Site Reaction

21 (75%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Fatigue
7 (25%)
Skin And Subcutaneous Tissue Disorders - 5 (17.9%)
Other, Specify

0 (0.0%)

2 (7.7%)

0 (0.0%)

0 (0.0%)

0 (0%)

0 (0.0%)

Pruritus

3 (10.7%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Arthralgia

3 (10.7%)

0 (0.0%)

0 (0%)

0 (0.0%)

Urticaria

3 (10.7%)

0 (0.0%)

0 (0%)

0 (0.0%)

Dyspnea

0 (0%)

0 (0.0%)

2 (7.7%)

0 (0.0%)

Hypertension

1 (3.6%)

1 (3.6%)

1 (3.8%)

0 (0%)

Nausea

1 (3.6%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Rash Maculo-Papular

1 (3.6%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Alanine Aminotransferase Increased

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Alkaline Phosphatase Increased

0 (0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Allergic Reaction

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Anemia

0 (0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Anorexia

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Aspartate Aminotransferase Increased

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Bone Pain

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Chills

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Constipation

0 (0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Diarrhea

1 (3.6%)

1 (3.6%)

0 (0%)

0 (0%)

Dizziness

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Edema Limbs

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Fever

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Flu Like Symptoms

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Generalized Muscle Weakness

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Headache

0 (0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Hot Flashes

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Hypophosphatemia

0 (0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Lymphocyte Count Decreased
1 (3.6%)
Musculoskeletal And Connective Tissue 0 (0%)
Disorders - Other, Specify

0 (0.0%)

0 (0%)

0 (0.0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Myalgia

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

Pain

0 (0%)

0 (0.0%)

1 (3.8%)

0 (0.0%)

Skin Infection

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)

White Blood Cell Decreased

1 (3.6%)

0 (0.0%)

0 (0%)

0 (0.0%)
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